Last reviewed · How we verify

Folia Biotech Inc. — Portfolio Competitive Intelligence Brief

Folia Biotech Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PAL PAL marketed Topical anti-inflammatory/analgesic PPAR-α; endocannabinoid system Pain management; Dermatology
TIV TIV marketed Inactivated influenza vaccine Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Brigham and Women's Hospital · 1 shared drug class
  4. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
  5. Fluart Innovative Vaccine Ltd, Hungary · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Green Cross Corporation · 1 shared drug class
  8. Ab&B Bio-tech Co., Ltd.JS · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Folia Biotech Inc.:

Cite this brief

Drug Landscape (2026). Folia Biotech Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/folia-biotech-inc. Accessed 2026-05-16.

Related